top of page
Search

Onco-Summaries: Daily Oncology Updates at a Glance

16/02/2026













Phase 3 LIBRETTO-432 trial of adjuvant selpercatinib met the EFS endpoint in RET fusion positive NSCLC (Ref)


Eli Lilly and Company announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of selpercatinib (Retevmo; RET kinase inhibitor) as an adjuvant therapy versus placebo in patients with early-stage (II-IIIA) RET fusion-positive NSCLC.


  • The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed EFS


  • OS results trended in favor of selpercatinib, but were immature at the time of this analysis with few events observed


  • The overall safety profile of selpercatinib in LIBRETTO-432 was generally consistent with previously reported trials in the selpercatinib development program

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page